Development of nonhuman adenoviruses as vaccine vectors
Identifieur interne : 000990 ( Pmc/Checkpoint ); précédent : 000989; suivant : 000991Development of nonhuman adenoviruses as vaccine vectors
Auteurs : Dinesh S. Bangari ; Suresh K. MittalSource :
- Vaccine [ 0264-410X ] ; 2005.
Abstract
Human adenoviral (HAd) vectors have demonstrated great potential as vaccine vectors. Preclinical and clinical studies have demonstrated the feasibility of vector design, robust antigen expression and protective immunity using this system. However, clinical use of adenoviral vectors for vaccine purposes is anticipated to be limited by vector immunity that is either preexisting or develops rapidly following the first inoculation with adenoviral vectors. Vector immunity inactivates the vector particles and rapidly removes the transduced cells, thereby limiting the duration of transgene expression. Due to strong vector immunity, subsequent use of the same vector is usually less efficient. In order to circumvent this limitation, nonhuman adenoviral vectors have been proposed as alternative vectors. In addition to eluding HAd immunity, these vectors possess most of the attractive features of HAd vectors. Several replication-competent or replication-defective nonhuman adenoviral vectors have been developed and investigated for their potential as vaccine delivery vectors. Here, we review recent advances in the design and characterization of various nonhuman adenoviral vectors, and discuss their potential applications for human and animal vaccination.
Url:
DOI: 10.1016/j.vaccine.2005.08.101
PubMed: 16297508
PubMed Central: 1462960
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:1462960Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of nonhuman adenoviruses as vaccine vectors</title>
<author><name sortKey="Bangari, Dinesh S" sort="Bangari, Dinesh S" uniqKey="Bangari D" first="Dinesh S." last="Bangari">Dinesh S. Bangari</name>
</author>
<author><name sortKey="Mittal, Suresh K" sort="Mittal, Suresh K" uniqKey="Mittal S" first="Suresh K." last="Mittal">Suresh K. Mittal</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">16297508</idno>
<idno type="pmc">1462960</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1462960</idno>
<idno type="RBID">PMC:1462960</idno>
<idno type="doi">10.1016/j.vaccine.2005.08.101</idno>
<date when="2005">2005</date>
<idno type="wicri:Area/Pmc/Corpus">000779</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000779</idno>
<idno type="wicri:Area/Pmc/Curation">000779</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000779</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000990</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000990</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Development of nonhuman adenoviruses as vaccine vectors</title>
<author><name sortKey="Bangari, Dinesh S" sort="Bangari, Dinesh S" uniqKey="Bangari D" first="Dinesh S." last="Bangari">Dinesh S. Bangari</name>
</author>
<author><name sortKey="Mittal, Suresh K" sort="Mittal, Suresh K" uniqKey="Mittal S" first="Suresh K." last="Mittal">Suresh K. Mittal</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">Human adenoviral (HAd) vectors have demonstrated great potential as vaccine vectors. Preclinical and clinical studies have demonstrated the feasibility of vector design, robust antigen expression and protective immunity using this system. However, clinical use of adenoviral vectors for vaccine purposes is anticipated to be limited by vector immunity that is either preexisting or develops rapidly following the first inoculation with adenoviral vectors. Vector immunity inactivates the vector particles and rapidly removes the transduced cells, thereby limiting the duration of transgene expression. Due to strong vector immunity, subsequent use of the same vector is usually less efficient. In order to circumvent this limitation, nonhuman adenoviral vectors have been proposed as alternative vectors. In addition to eluding HAd immunity, these vectors possess most of the attractive features of HAd vectors. Several replication-competent or replication-defective nonhuman adenoviral vectors have been developed and investigated for their potential as vaccine delivery vectors. Here, we review recent advances in the design and characterization of various nonhuman adenoviral vectors, and discuss their potential applications for human and animal vaccination.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">8406899</journal-id>
<journal-id journal-id-type="pubmed-jr-id">7945</journal-id>
<journal-id journal-id-type="nlm-ta">Vaccine</journal-id>
<journal-title>Vaccine</journal-title>
<issn pub-type="ppub">0264-410X</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">16297508</article-id>
<article-id pub-id-type="pmc">1462960</article-id>
<article-id pub-id-type="doi">10.1016/j.vaccine.2005.08.101</article-id>
<article-id pub-id-type="manuscript">NIHMS9423</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Development of nonhuman adenoviruses as vaccine vectors</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Bangari</surname>
<given-names>Dinesh S.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Mittal</surname>
<given-names>Suresh K.</given-names>
</name>
<xref rid="FN1" ref-type="author-notes">*</xref>
</contrib>
<aff id="A1">Laboratory of Gene Therapy, Department of Veterinary Pathobiology, Purdue University, West Lafayette, IN 47907, USA</aff>
</contrib-group>
<author-notes><corresp id="FN1">* <bold>Corresponding author</bold>
Laboratory of Gene Therapy, Department of Veterinary Pathobiology, Purdue University, West Lafayette, IN 47907, USA, Email: <email>mittal@purdue.edu</email>
Fax: 765-494-9830</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>3</day>
<month>5</month>
<year>2006</year>
</pub-date>
<pub-date pub-type="epub"><day>23</day>
<month>9</month>
<year>2005</year>
</pub-date>
<pub-date pub-type="ppub"><day>13</day>
<month>2</month>
<year>2006</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>13</day>
<month>2</month>
<year>2007</year>
</pub-date>
<volume>24</volume>
<issue>7</issue>
<fpage>849</fpage>
<lpage>862</lpage>
<abstract><p id="P1">Human adenoviral (HAd) vectors have demonstrated great potential as vaccine vectors. Preclinical and clinical studies have demonstrated the feasibility of vector design, robust antigen expression and protective immunity using this system. However, clinical use of adenoviral vectors for vaccine purposes is anticipated to be limited by vector immunity that is either preexisting or develops rapidly following the first inoculation with adenoviral vectors. Vector immunity inactivates the vector particles and rapidly removes the transduced cells, thereby limiting the duration of transgene expression. Due to strong vector immunity, subsequent use of the same vector is usually less efficient. In order to circumvent this limitation, nonhuman adenoviral vectors have been proposed as alternative vectors. In addition to eluding HAd immunity, these vectors possess most of the attractive features of HAd vectors. Several replication-competent or replication-defective nonhuman adenoviral vectors have been developed and investigated for their potential as vaccine delivery vectors. Here, we review recent advances in the design and characterization of various nonhuman adenoviral vectors, and discuss their potential applications for human and animal vaccination.</p>
</abstract>
<contract-num rid="CA1">R01 CA110176-01A1</contract-num>
<contract-sponsor id="CA1">National Cancer Institute : NCI</contract-sponsor>
</article-meta>
</front>
</pmc>
<affiliations><list></list>
<tree><noCountry><name sortKey="Bangari, Dinesh S" sort="Bangari, Dinesh S" uniqKey="Bangari D" first="Dinesh S." last="Bangari">Dinesh S. Bangari</name>
<name sortKey="Mittal, Suresh K" sort="Mittal, Suresh K" uniqKey="Mittal S" first="Suresh K." last="Mittal">Suresh K. Mittal</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000990 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000990 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= CovidV2 |flux= Pmc |étape= Checkpoint |type= RBID |clé= PMC:1462960 |texte= Development of nonhuman adenoviruses as vaccine vectors }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:16297508" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a CovidV2
This area was generated with Dilib version V0.6.33. |